Patient dies in early trial of an experimental CAR-T therapy for multiple sclerosis
Published
Bristol Myers Squibb reported that a participant in its Phase 1 study developed movement problems that didn't improve with standard treatment, later got septic pneumonia and died. The company says other complications the patient had make the cause hard to pin down. CAR-T treatments for autoimmune diseases remain experimental and are available only in clinical trials.
Source: STAT
This is a plain-language summary. Read the original source for full details.